ZACHARY FUSSELL: Open Payments
NPI 1861114407 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,053 in 53 payments from 10 companies in 2025. Trend: 2023 $666 · 2024 $395 · 2025 $8,053
Speaker / faculty: $6,813Food & beverage: $1,094Travel & lodging: $147
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $7,186 |
| ABBVIE INC. | 8 | $254 |
| Braeburn Inc. | 3 | $172 |
| Neurocrine BioSciences, Inc. | 9 | $167 |
| Indivior Inc. | 6 | $111 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Alpha Cognition USA, Inc. | 1 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: REXULTI, VRAYLAR, BRIXADI, INGREZZA, SUBLOCADE, AUSTEDO XR, Zunveyl, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
